CD274 and non-small cell lung carcinoma: Several phase 3 clinical trials7,8,10,11,12 previously reported that ICI plus chemotherapy exhibited superior outcomes compared with standard chemotherapy for patients with advanced NSCLC without oncogenic driver alterations, regardless of PD-L1 TPS.